We are live on ! Find out more
TNXP icon

Tonix Pharmaceuticals
TNXP

12 hedge funds and large institutions have $52M invested in Tonix Pharmaceuticals in 2021 Q1 according to their latest regulatory filings, with 8 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 1 closing their positions.

New
Increased
Maintained
Reduced
Closed

909% more capital invested

Capital invested by funds: $5.16M → $52M (+$46.9M)

700% more first-time investments, than exits

New positions opened: 8 | Existing positions closed: 1

200% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 1

140% more funds holding

Funds holding: 5 → 12 (+7)

0% more ownership

Funds ownership: 0% → 0% (+0%)

Holders
12
Holders Change
+7
Holders Change %
+140%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
8
Increased
3
Reduced
1
Closed
1
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
+$15.3M
2
Renaissance Technologies
Renaissance Technologies
New York
+$9.94M
3
BlackRock
BlackRock
New York
+$7.65M
4
Geode Capital Management
Geode Capital Management
Massachusetts
+$3.06M
5
Millennium Management
Millennium Management
New York
+$1.53M

Top Sellers

Rank Fund Capital Flow
1
GCP
GSA Capital Partners
United Kingdom
-$765K
2
Squarepoint
Squarepoint
New York
-$459K
3
N
Natixis
France
-$36K
4
RFA
Reilly Financial Advisors
California
-$17K
5
LFG
Larson Financial Group
Missouri
-$14K
Name Holding Trade Value Shares
Change 		Change in
Stake
MA
26
MONECO Advisors
Connecticut
$45K – – –
Principal Financial Group
27
Principal Financial Group
Iowa
$37K – – –
HighTower Advisors
28
HighTower Advisors
Illinois
$33K – – –
FMBTD
29
First Midwest Bank Trust Division
Illinois
$32K – – –
CSS
30
Cubist Systematic Strategies
Connecticut
$27K – – –
EH
31
Equitable Holdings
New York
$26K – – –
GC
32
Grimes & Company
Massachusetts
$26K – – –
SGI
33
Summit Global Investments
Utah
$26K – – –
NFG
34
Norris Financial Group
South Carolina
$23.7K – – –
VHAM
35
Van Hulzen Asset Management
California
$23K – – –
Creative Planning
36
Creative Planning
Kansas
$21K – – –
Wells Fargo
37
Wells Fargo
California
$21K – – –
Cerity Partners
38
Cerity Partners
New York
$20K – – –
VFA
39
Valeo Financial Advisors
Indiana
$20K – – –
PWM
40
Purus Wealth Management
California
$19K – – –
SWM
41
Spire Wealth Management
Virginia
$19K – – –
CAN
42
Cetera Advisor Networks
California
$17K – – –
SSA
43
Schonfeld Strategic Advisors
New York
$17K – – –
SFS
44
Sowell Financial Services
Arkansas
$17K – – –
CM
45
Capula Management
Cayman Islands
$16K – – –
CIBC Asset Management
46
CIBC Asset Management
Ontario, Canada
$16K – – –
LCC
47
Lincoln Capital Corp
Rhode Island
$15K – – –
ZIG
48
Zuckerman Investment Group
Illinois
$15K – – –
SAF
49
Smith Anglin Financial
Texas
$13K – – –
TRCT
50
Tower Research Capital (TRC)
New York
$9K – – –
1
2
3

TNXP Hedge Fund Activity: Q1 2021 in Review

12 of the 5,695 institutional investors tracked by Wall St. Rank reported a position in Tonix Pharmaceuticals (TNXP) for Q1 2021, worth a combined $52M — up 909% from $5.16M a quarter earlier.

Buyers outnumbered sellers: 8 funds opened new TNXP positions and 1 closed out — a net gain of 7 holders — while 3 added to existing stakes and 1 trimmed.

The largest buyer was Vanguard Group, adding an estimated $15.3M. The largest seller was GSA Capital Partners, cutting an estimated $765K.

  • 12 institutional investors held Tonix Pharmaceuticals (TNXP) as of Q1 2021, up from 5 in Q4 2020.
  • Funds reported $52M of Tonix Pharmaceuticals stock for Q1 2021, up 909% quarter-over-quarter.
  • 8 funds opened new Tonix Pharmaceuticals positions in Q1 2021 and 1 closed out, a net change of +7 holders.
  • The largest Tonix Pharmaceuticals buyer in Q1 2021 was Vanguard Group, an estimated $15.3M added.
  • The largest Tonix Pharmaceuticals seller in Q1 2021 was GSA Capital Partners, an estimated $765K sold.

Based on aggregated 13F filings for Q1 2021.